Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12618000228280
Ethics application status
Approved
Date submitted
2/02/2018
Date registered
12/02/2018
Date last updated
7/07/2022
Date data sharing statement initially provided
11/03/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
Introducing cashew nuts during infancy – The Cashew Study.
Scientific title
Regular intake of cashew nut paste in infant diets between six to twelve months of age to reduce cashew nut allergy at 1 year of age - a dose response randomised controlled trial.
Secondary ID [1] 293952 0
none
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Food allergy 306454 0
Tree Nut Hypersensitivity 306486 0
Condition category
Condition code
Inflammatory and Immune System 305540 305540 0 0
Allergies

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Arm 1: The families will be provided with the updated 2016 ASCIA infant feeding and allergy prevention guidelines (www.allergy.org.au). In addition, the families will be advised to orally give their infant 1 teaspoon of cashew nut spread (100% cashew nuts) mixed with their solid foods three times per week from 6-8 until 12 months of age . Families will be provided with jars of the cashew nut spread to use..
Arm 2: The families will be provided with the updated 2016 ASCIA infant feeding and allergy prevention guidelines. In addition, the families will be advised to orally give their infant increasing amounts of the cashew nut spread (100% cashew nuts) mixed with their solid foods three times per week. The increasing dosage regime will be 1 teaspoon from 6-7 months, 2 teaspoons from 8-9 months and 3 teaspoons from 10 months of age with the intervention period of from 6-8 until 12 months of age . If a participant commences at 8 months of age the starting dose will be 2 teaspoons. Families will be provided with jars of the cashew nut spread to use.

Compliance: All arm 1 and arm 2 participating families will be contacted monthly via a 10 minute telephone call and asked about how much of the Cashew Nut spread their infant had eaten over the preceding week.
Intervention code [1] 300218 0
Prevention
Comparator / control treatment
The families will be provided with the updated 2016 ASCIA infant feeding and allergy prevention guidelines..
Control group
Active

Outcomes
Primary outcome [1] 304674 0
Cashew nut-specific IgG4 concentration in infant blood measured using the ImmunoCAP 250 system (Phadia AB, Uppsala, Sweden)..
Timepoint [1] 304674 0
At 1 year of age.
Secondary outcome [1] 342734 0
Sensitization to cashew nut measured by cashew nut-specific IgE concentration in infant blood measured using the ImmunoCAP 250 system (Phadia AB, Uppsala, Sweden).
Timepoint [1] 342734 0
At 1 year of age.
Secondary outcome [2] 342735 0
Sensitization to cashew nut measured by cashew nut skin prick testing.
Timepoint [2] 342735 0
At 1 year of age.
Secondary outcome [3] 342736 0
Medically diagnosed cashew nut allergy by a medical officer during the medically supervised cashew nut food challenge appointment at 1 year of age.
Timepoint [3] 342736 0
At 1 year of age.
Secondary outcome [4] 342737 0
Medically diagnosed eczema between 6 to 12 months of age via parent self-report or via examination by a medical officer during the 1 year of age appointment.
Timepoint [4] 342737 0
At 1 year of age.
Secondary outcome [5] 342738 0
Medically diagnosed wheeze between 6 to 12 months of age via parent self-report or via examination by a medical officer during the 1 year of age appointment.
Timepoint [5] 342738 0
At 1 year of age.

Eligibility
Key inclusion criteria
Eligible participants will be infants who are born greater than or equal to 37 weeks gestation.
Minimum age
6 Months
Maximum age
8 Months
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Infants with a feeding difficulty that are unable to eat solid foods prior to 8 months of age.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation was concealed by use of sealed opaque envelopes.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Analysis Plan: For the primary and secondary outcome measurements with detection thresholds (cashew nut-specific IgG4 and IgE concentrations) Tobit regression models will be used, with treatment effects described using ratios of means and 95% confidence intervals. The secondary binary outcomes food allergy, food sensitisation, eczema and wheeze will be analysed using log binomial regression models, with treatment effects described using relative risks and 95% confidence intervals.

Sample size calculations: The primary outcome for this study will be the difference in median cashew nut-specific IgG4 concentrations between the intervention group 1 and the control group. Using results from our previous egg introduction in infancy trial, the effect of the intervention of regular egg introduction versus egg avoidance on egg-specific IgG4 concentrations, for 80% power and 95% confidence (alpha-value 0.05), we would require 30 infants per group. As we require successful blood collections at 1 year of age for this primary outcome result, and our infant blood collection rate has been 60%, along with an expected completion rate of at least 80%, we would need to randomise 64 infants into each group. Thus our total sample size will be 3 groups of 64 infants = 192 infants.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
26/03/2018
Actual
4/07/2018
Date of last participant enrolment
Anticipated
Actual
18/01/2021
Date of last data collection
Anticipated
27/08/2021
Actual
18/08/2021
Sample size
Target
192
Accrual to date
Final
196
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 11535 0
Joondalup Health Campus - Joondalup
Recruitment postcode(s) [1] 23562 0
6027 - Joondalup

Funding & Sponsors
Funding source category [1] 298581 0
Charities/Societies/Foundations
Name [1] 298581 0
Australian Food Allergy Foundation
Country [1] 298581 0
Australia
Primary sponsor type
Individual
Name
Dr Debra Palmer
Address
Telethon Kids Institute
Roberts Rd Subiaco WA 6008
Country
Australia
Secondary sponsor category [1] 297735 0
None
Name [1] 297735 0
Address [1] 297735 0
Country [1] 297735 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 299546 0
Human Research Ethics Committee of the Joondalup Health Campus
Ethics committee address [1] 299546 0
Ethics committee country [1] 299546 0
Australia
Date submitted for ethics approval [1] 299546 0
19/11/2017
Approval date [1] 299546 0
12/01/2018
Ethics approval number [1] 299546 0
1740

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 80802 0
Dr Debra Palmer
Address 80802 0
Level 7, Telethon Kids Institute, Perth Children's Hospital, 15 Hospital Ave Nedlands WA 6009
Country 80802 0
Australia
Phone 80802 0
+61 410 851 607
Fax 80802 0
Email 80802 0
debbie.palmer@telethonkids.org.au
Contact person for public queries
Name 80803 0
Debra Palmer
Address 80803 0
Level 7, Telethon Kids Institute, Perth Children's Hospital, 15 Hospital Ave Nedlands WA 6009
Country 80803 0
Australia
Phone 80803 0
+61 410 85 1607
Fax 80803 0
Email 80803 0
debbie.palmer@telethonkids.org.au
Contact person for scientific queries
Name 80804 0
Debra Palmer
Address 80804 0
Level 7, Telethon Kids Institute, Perth Children's Hospital, 15 Hospital Ave Nedlands WA 6009
Country 80804 0
Australia
Phone 80804 0
+61 410 851 607
Fax 80804 0
Email 80804 0
debbie.palmer@telethonkids.org.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
After de-identification, individual participant data underlying published results only.
When will data be available (start and end dates)?
Beginning 6 months after and ending 5 years following main results publication
Available to whom?
Case by case basis at the discretion of CI Debbie Palmer
Available for what types of analyses?
For IPD meta-analyses
How or where can data be obtained?
Access subject to approvals by CI Debbie Palmer


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.